Table 1.
Baseline characteristics in patients with and without the combined endpoint (n = 227)
| |
All (n = 227) |
No death, MI or HF (n = 142) |
Death, MI or HF (n = 85) |
|
|---|---|---|---|---|
| Variables | n (%) | n (%) | n (%) | P |
|
Demographics: |
|
|
|
|
| Age (median, 25th–75th perc.) |
67 (59–77) |
62 (56–74) |
74 (63–80) |
<0.001 |
| Men |
172 (76) |
111 (78) |
61 (72) |
0.276 |
|
Risk factors: |
|
|
|
|
| Hypertension |
121 (53) |
63 (44) |
58 (68) |
<0.001 |
| Diabetes Mellitus |
51 (22) |
29 (20) |
22 (26) |
0.340 |
| Current smoker (missing n = 6) |
43 (19) |
33 (23) |
10 (13) |
0.049 |
|
Previous cardiovascular disease: |
|
|
|
|
| Myocardial infarction |
56 (25) |
31 (22) |
25 (30) |
0.200 |
| Heart Failure |
19 (8) |
2 (1) |
17 (20) |
<0.001 |
| Revascularization, PCI |
33 (15) |
23 (16) |
10 (12) |
0.359 |
| Revascularization, CABG |
10 (4) |
4 (3) |
6 (7) |
0.132 |
| Stroke |
17 (8) |
10 (7) |
7 (8) |
0.741 |
|
Laboratory measurements |
|
|
|
|
| NTproBNP 24 h (median, 25th–75th perc.) (n = 189)) |
1220 (535–3465) |
724 (303–1887) |
2300 (1030–26040) |
<0.001 |
| eGFR (median, 25th–75th perc.) (n = 220) |
81 (58–110) |
92 (72–116) |
66 (40–96) |
<0.001 |
| Troponin I (median, 25th–75th perc.) (n = 207) |
3.5 (0.41–10.4) |
2.4 (0.28–9.6) |
4.4 (0.57–10.7) |
0.118 |
|
Index Diagnosis |
|
|
|
|
| Myocardial infarction |
188 (83) |
119 (84) |
69 (81) |
0.612 |
|
Measurements of LV function |
|
|
|
|
| EF simpson (median, 25th–75th perc.) |
49 (41–56) |
45 (35–52) |
52 (45–58) |
<0.001 |
| WMSI (median, 25th–75th perc.) |
1.06 (1.00–1.33) |
1.14 (1.00–1.56) |
1.00 (1.00–1.16) |
<0.001 |
|
Intervention during admission |
|
|
|
|
| Coronary angiography |
192 (85) |
132 (93) |
60 (70) |
<0.001 |
| PCI |
109 (48) |
81 (57) |
28 (33) |
<0.001 |
| CABG |
25 (11) |
13 (9) |
12 (14) |
0.248 |
|
Treatment at discharge |
|
|
|
|
| Betablocker |
211 (93) |
135 (95) |
76 (89) |
0.114 |
| Statin |
209 (92) |
137 (96) |
72 (85) |
0.003 |
| ASA |
217 (96) |
141 (99) |
76 (89) |
0.001 |
| Clopidogrel |
148 (65) |
103 (73) |
45 (53) |
0.003 |
| ACE inhibitor/A2 blocker | 173 (76) | 101 (71) | 72 (85) | 0.012 |